Crypto investor Will Harbone has launched LongGame, a $40 million enterprise capital fund devoted to advancing longevity biotechnology, in keeping with a Dec. 12 assertion shared with CryptoSlate.
The initiative seeks to revolutionize human well being by extending wholesome lifespans over three a long time by investments in modern fields like stem cell analysis, gene modifying, and senolytics.
LongGame targets early-stage biotech startups with scalable applied sciences, emphasizing pre-seed and seed investments. Past funding, the initiative goals to bridge biotechnology and decentralized science (DeSci), fostering collaboration between conventional life sciences and rising decentralized applied sciences.
The fund plans to combine instruments like DAOs to streamline drug discovery and encourage patient-driven analysis. Over the following 4 years, LongGame intends to strategically allocate its capital whereas supporting world scalability for its portfolio corporations.
The management workforce at LongGame contains COO Chloe Northcott, previously of Geometry, and Particular Advisor Sebastian A. Brunemeier, Basic Companion at Healthspan Capital. Dr. Manish Chamoli, the fund’s chief scientific officer, brings deep experience in ageing biology and longevity analysis from his tenure on the Buck Institute. This workforce will collaborate with specialists throughout numerous fields in medical science and biotechnology to advance its mission.
Along with his workforce, Harbone envisions leveraging blockchain improvements similar to tokenization, crowdfunding, and liquidity options to deal with funding gaps in longevity analysis. These mechanisms goal to democratize entry to life-extending therapies, guaranteeing they profit a broad inhabitants relatively than remaining unique to the rich.
He defined:
“Our objective is to fund therapies that do extra than simply lengthen life; we’re in search of options that radically develop the wholesome human lifespan—by 30 years or extra. We’re tackling the foundation causes of ageing, not simply the signs, and we wish to make sure that these life-extending therapies are accessible to the plenty, not simply the rich.”
Harborne believes longevity innovation can doubtlessly disrupt world industries, very like crypto reshaped conventional finance.
In the meantime, this fund transfer aligns with a broader pattern of crypto leaders getting into the longevity area. Final 12 months, Coinbase CEO Brian Armstrong co-founded NewLimit, a biotech agency that raised $40 million to advance age-related therapies.